PAVmed (NASDAQ:PAVM) Stock Falls 7.3% – What’s Next?

Shares of PAVmed Inc. (NASDAQ:PAVM) fell 7.3% during trading on Monday. The company traded as low as $2.66 and last traded at $2.66. 7,386 shares traded hands during trading, a decline of 77% from the average session volume of 31,706 shares. The stock had previously closed at $2.87.

Analyst Upgrades and Downgrades

PAVM has been the topic of several research analyst reports. Weiss Ratings lowered shares of PAVmed from a “sell (d)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. Ascendiant Capital Markets reduced their target price on shares of PAVmed from $65.00 to $56.00 and set a “buy” rating for the company in a report on Monday, June 8th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, PAVmed presently has a consensus rating of “Hold” and a consensus target price of $56.00.

PAVmed Stock Performance

The firm has a market capitalization of $21.27 million, a price-to-earnings ratio of -0.17 and a beta of 0.69. The company has a fifty day moving average of $4.58 and a two-hundred day moving average of $6.15. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.19 and a current ratio of 1.19.

Institutional Investors Weigh In On PAVmed

A hedge fund recently bought a new stake in PAVmed stock. Two Seas Capital LP acquired a new position in PAVmed Inc. (NASDAQ:PAVM) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 461,539 shares of the company’s stock, valued at approximately $2,742,000. Two Seas Capital LP owned approximately 46.15% of PAVmed as of its most recent SEC filing. 19.93% of the stock is currently owned by hedge funds and other institutional investors.

PAVmed Company Profile

PAVmed Inc is a medical device and healthcare company focused on developing and commercializing diagnostic and therapeutic technologies. The company has historically pursued products designed to address significant unmet needs in areas such as cancer detection, gastrointestinal health and chronic disease management.

Through its subsidiaries and affiliated businesses, PAVmed has been associated with technologies including EsoGuard, a molecular test intended to identify patients at elevated risk for esophageal precancer, and EsoCheck, a swallowable balloon device used to collect cells from the esophagus for testing.